Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer

scientific article

Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.YGYNO.2011.05.022
P698PubMed publication ID21664657

P2093author name stringD Scott McMeekin
Robert S Mannel
Joan L Walker
Lisa M Landrum
Johnny Hyde
Kathleen N Moore
P2860cites workPhase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the GQ33335882
Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinomaQ33536730
Relationship between cisplatin administration and the development of ototoxicityQ34495455
Ototoxicity after intraperitoneal chemotherapy: a case reportQ36791118
Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion ratesQ36995650
Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancerQ37613377
The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitizationQ37770689
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicityQ42554765
Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.Q43230496
Complications associated with intraperitoneal chemotherapy cathetersQ43558713
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancerQ44044542
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.Q50512108
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.Q51301047
Intraperitoneal chemotherapy for ovarian cancer: 2009 goals.Q51797268
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.Q53263238
Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter systemQ70188668
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusionQ72880127
Clinical features of hypersensitivity reactions to carboplatinQ73181371
Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con viewQ81192248
Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinomaQ83170387
Intraperitoneal therapy for ovarian cancer: why has it not become standard?Q83917354
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectcisplatinQ412415
paclitaxelQ423762
uterine tubeQ1233836
fallopian tube cancerQ4818922
fallopian tube carcinomaQ18554948
phase II clinical trialQ42824440
P304page(s)527-531
P577publication date2011-06-12
P1433published inGynecologic OncologyQ5625182
P1476titlePhase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
P478volume122

Reverse relations

cites work (P2860)
Q90431035Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer
Q44019385Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study
Q37735208Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer.

Search more.